SCHEMBL17780901

SCHEMBL17780901

COc1cc2ncnc(-c3cc(N)cnc3N)c2cc1OC

nearest known ligand 0.61

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KIT P10721 6/20 0.61
EGFR P00533 10/20 0.47
RET P07949 2/20 0.45
KDR P35968 2/20 0.45
ENPP1 P22413 1/20 0.43
GAK O14976 1/20 0.43
SRC P12931 1/20 0.43
CLK1 P49759 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
PDPK1 O15530 2/20 0.43
LCK P06239 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182709 0.79 KIT (0.59) KITEGFRRETKDRENPP1
Hydrochloric Acid SCHEMBL6181793 0.78 KIT (0.57) KITEGFRRETKDRENPP1
SCHEMBL15504611 0.76 KIT (1.00) KITEGFRRETKDRCLK1
SCHEMBL5569432 0.75 KIT (0.69) KITEGFRRETKDRENPP1
SCHEMBL30103402 0.75 PDE5A (0.57) KITEGFRRETKDRENPP1
SCHEMBL3166753 0.75 PDE5A (0.57) KITEGFRRETKDRENPP1
SCHEMBL3948832 0.74 KIT (0.53) KITEGFRRETKDRENPP1
SCHEMBL5568255 0.72 KIT (0.64) KITEGFRRETKDRENPP1
SCHEMBL2926080 0.72 KIT (0.67) KITEGFRRETKDR
SCHEMBL8172203 0.71 KIT (0.59) KITEGFRRETKDRPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200392110-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2020-12-17 US disclosed
EP-3415501-B9 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2020-12-02 EP disclosed
US-10676462-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2020-06-09 US disclosed
EP-3415501-B1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2020-04-08 EP disclosed
US-10501442-B2 Quinoline derivative ONO PHARMACEUTICALS CO., LTD. (JP) 2019-12-10 US disclosed
US-20190135785-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2019-05-09 US disclosed
US-10208022-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2019-02-19 US disclosed
EP-3415501-A1 QUINOLINE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2018-12-19 EP disclosed
US-20180258072-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2018-09-13 US disclosed
US-9994549-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2018-06-12 US disclosed
US-20170088542-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2017-03-30 US disclosed
US-9573935-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2017-02-21 US disclosed
US-20160168121-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 US disclosed
EP-3026045-A1 QUINOLINE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2016-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392110-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 KIT 74/4885EGFR 17/4885RET 32/4885
US-10501442-B2 Quinoline derivative FLT3, AXL, ERBB2 KIT 74/4885EGFR 17/4885RET 32/4885
US-20180258072-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 KIT 74/4885EGFR 17/4885RET 32/4885
US-10208022-B2 Quinoline derivative FLT3, AXL, ERBB2 KIT 74/4885EGFR 17/4885RET 32/4885
US-20160168121-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 KIT 81/4885EGFR 24/4885RET 29/4885
US-20170088542-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 KIT 74/4885EGFR 17/4885RET 32/4885
US-10676462-B2 Quinoline derivative FLT3, AXL, ERBB2 KIT 74/4885EGFR 17/4885RET 32/4885
US-20190135785-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 KIT 74/4885EGFR 17/4885RET 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.